bioRxivCancer BiologyPreprint
MRPL47 as a Novel Mitochondrial Biomarker for Early Detection and Therapeutic Response in Ovarian Cancer
Meenakshi Pradeep, Ishaque Pulikkal Kadamberi, Jasmine GeorgeiD, Yueying GaoiD, Camilla DagumiD, Ajay Nair, Shirng-Wern Tsaih, Anjali GeethadeviiD, A. Nair, Elizabeth E. HoppiD, Denise S. UyariD, William Hampton BradleyiD, Janet Sue RaderiD, Yongsheng LiiD, Pradeep Chaluvally–RaghavaniD, Akinyemi I. OjesinaiD
- Citations
- 0
Abstract
MRPL47 (Mitochondrial Ribosomal Protein Large Subunit 47) gene in chromosome 3q26 encodes a protein that is part of the large subunit of the mitochondrial ribosome. We observed that MRPL47 is frequently amplified and overexpressed in ovarian cancer samples. Importantly, increased expression of MRPL47 mRNA is associated with high levels of MRPL47 protein in ovarian cancer patients. High expression of MRPL47 is also associated with poor overall and recurrence free survival of ovarian cancer patients. Notably, MRPL47 improved metabolic fitness by enhancing cellular respiration, and glycolysis in cancer cells. Gene set enrichment analysis and target specific knockdown assays revealed that MYC transcription factor regulates MRPL47 expression. Furthermore, MRPL47 was identified very high in the plasma samples of ovarian cancer patients compared to those of healthy volunteers. MRPL47 was also associated with cisplatin resistance, whereas its expression predicted sensitivity to cisplatin therapy. Taken together, we demonstrated that MRPL47 can be used as a diagnostic biomarker for ovarian cancer and other cancers with 3q26 chromosomal amplification.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Suppression of Ovarian Cancer Cell Proliferation is Associated with Upregulation of Cell-Matrix Adhesion Programs and Integrin-β4-Induced Cell Protection from Cisplatin.
Sadaf Farsinejad, Daniel Centeno, … Marcin Iwanicki·CancersPeer-reviewed·Apr 27, 2025
- A 15-Gene prognostic signature with TFAP2B functioning in Platinum Resistance of Ovarian Carcinoma
Yang Hu, Ping Wang, … Weibing Qin·bioRxiv·Sep 7, 2024
- Protein Expression Patterns in ovarian cancer cells Associated with Monofunctional Platinums Treatment
L. Arzuman, M. A. Moni, … F. Huq·bioRxiv·May 7, 2019
- The significance of microRNA genes expression in ovarian cancer cell lines resistant to cytotoxic drugs
D. Kazmierczak, K. Jopek, … R. Januchowski·bioRxiv·Dec 4, 2019
- RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells
Alexandra N. Spirtos, Marwa W. Aljardali, … Cristel V. Camacho·bioRxiv·Aug 20, 2024
- Loss of the predicted cell adhesion molecule MPZL3 promotes EMT and chemoresistance in ovarian cancer
Ya-Yun Cheng, Beth L. Worley, … Nadine Hempel·Cancer Research CommunicationsPeer-reviewed·Jul 1, 2025